Clinical Trials Logo
  1. Home
  2. Granulomatosis With Polyangiitis
  3. NCT01750697

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Granulomatosis With Polyangiitis Clinical Trial

Official title:
A Phase IIA, International, Multicenter, Open-label, Uncontrolled Study to Evaluate The Safety And Pharmacokinetics of 4 × 375 mg/m2 Intravenous Rituximab in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Clinical Trial Summary

This Phase IIa international multicenter, open-label, uncontrolled study will evaluate the safety and pharmacokinetics of rituximab (MabThera/Rituxan) in pediatric participants with severe granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Participants will receive rituximab 375 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1, 8, 15 and 22.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01750697
Study type Interventional
Source Hoffmann-La Roche
Contact
Status Completed
Phase Phase 2
Start date May 23, 2013
Completion date May 10, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT01731561 - Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Phase 3
Completed NCT01862068 - Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)
Not yet recruiting NCT02126098 - Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis N/A
Terminated NCT01586858 - Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study N/A
Active, not recruiting NCT03919435 - TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Phase 1/Phase 2
Not yet recruiting NCT04871191 - Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Phase 2
Terminated NCT05376319 - PR3-AAV Resilient Remission or PRRR Phase 2
Not yet recruiting NCT05353179 - Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Early Phase 1
Completed NCT02169219 - Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Phase 4
Completed NCT01613599 - An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Active, not recruiting NCT05716334 - Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
Recruiting NCT04944524 - Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Phase 4
Completed NCT03430388 - Yellow Fever Vaccine in Patients With Rheumatic Diseases N/A
Completed NCT03410290 - Journey of Patients With Vasculitis From First Symptom to Diagnosis
Recruiting NCT03482479 - Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Phase 2
Active, not recruiting NCT01940094 - The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach Phase 3
Recruiting NCT01405807 - Alemtuzumab for ANCA Associated Refractory Vasculitis Phase 4
Active, not recruiting NCT01933724 - The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach Phase 3
Completed NCT05703802 - Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.
Active, not recruiting NCT03967925 - Rituximab and Belimumab Combination Therapy in PR3 Vasculitis Phase 2